SPY334.30-0.03 -0.01%
DIA273.67-0.23 -0.08%
IXIC11,104.75-3.32 -0.03%
新闻
FOLD
--
0.00%
--
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020
GlobeNewswire · 3天前
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3天前
New Strong Sell Stocks for July 31st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 07/31 11:42
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quar
GlobeNewswire · 07/28 11:00
Applied DNA's COVID-19 Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/20 11:34
Amicus Therapeutics secures $400M in debt financing
Amicus Therapeutics (NASDAQ:FOLD) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. T
seekingalpha · 07/17 17:00
Amicus Therapeutics shares are trading higher after the company announced it has secured a $400 million non-dilutive debt financing.
Benzinga · 07/17 13:49
Amicus Therapeutics Reiterates 2020 Galafold Sales Guidance Of $250-$260M
Benzinga · 07/17 11:37
Amicus Therapeutics Secures $400M Non-Dilutive Debt Financing
$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings  Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring
Benzinga · 07/17 11:36
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings  Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost.
GlobeNewswire · 07/17 11:32
Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)?
Insider Monkey · 07/13 01:16
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09
Two Patients Die in Audentes Gene Therapy Study, Heightening Concerns Over High-dose Treatments
-Stat News https://www.statnews.com/2020/06/28/two-patients-die-audentes-gene-therapy-study/
Stat News · 06/28 21:40
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%
Zacks · 06/22 14:23
Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering
Seeking Alpha - Article · 06/18 13:45
BTIG Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $19
BTIG analyst Dae Gon Ha initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Buy rating and announces Price Target of $19.
Benzinga · 06/17 10:25
Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant
Seeking Alpha - Article · 06/09 12:23
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 06/08 07:38
Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?
Zacks · 06/06 16:31
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
CRANBURY, N.J., June 04, 2020 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside.
GlobeNewswire · 06/04 11:00